Foundayo Pill in Dubai
The UAE is only the second country in the world to approve Foundayo™ (orforglipron) — a once-daily oral GLP-1 weight loss tablet developed by Eli Lilly. No injections. No food restrictions. No refrigeration. Just a pill you swallow at any time of day.
As a bariatric and weight management specialist practising in Dubai, I prescribe Foundayo to eligible patients as part of a medically supervised weight loss programme. On this page I explain exactly what Foundayo is, who it suits, what results to expect, its side effects, how it compares to Mounjaro and Ozempic — and where it sits relative to bariatric surgery, which for many patients with significant obesity remains the most effective and durable treatment available.
If you are considering starting Foundayo in Dubai under proper medical supervision, or want to understand whether surgery or medication is right for your situation, book a consultation.
What Is Foundayo? (Orforglipron Explained)
Foundayo is the brand name for orforglipron, a non-peptide, small-molecule GLP-1 receptor agonist. It was developed by Eli Lilly — the same company behind Mounjaro (tirzepatide) — and represents a genuine pharmacological breakthrough: the first GLP-1 weight loss medicine that works as an oral tablet.
Existing GLP-1 medications (Ozempic, Mounjaro, Wegovy, Saxenda) are all peptide-based. Because peptides are broken down by stomach acid and digestive enzymes, they must be administered by subcutaneous injection. Orforglipron is chemically different — a small organic molecule that survives digestion and can be absorbed through the gut wall after swallowing.
It was approved by the US FDA on 1 April 2026 and by the UAE’s Emirates Drug Establishment (EDE) in April 2026. The UAE became the second country in the world to authorise it. It is expected to be available in UAE pharmacies from May 2026.
Key Advantages of Foundayo Over Injectable GLP-1 Drugs
No injections — a daily tablet, ideal for patients who are needle-averse
No food or water restrictions — unlike oral semaglutide, which requires fasting for 30 minutes before and after
No refrigeration — stable at room temperature; important for UAE climate and travel
Lower cost — estimated AED 550–800/month vs AED 1,734–2,000/month for Mounjaro
Once-daily dosing — starting at 1 mg, titrated up to 6 mg, 12 mg, or 36 mg
The UAE is only the second country in the world to approve Foundayo™ (orforglipron) — a once-daily oral GLP-1 weight loss tablet developed by Eli Lilly. No injections. No food restrictions. No refrigeration. Just a pill you swallow at any time of day.
As a bariatric and weight management specialist practising in Dubai, I prescribe Foundayo to eligible patients as part of a medically supervised weight loss programme. On this page I explain exactly what Foundayo is, who it suits, what results to expect, its side effects, how it compares to Mounjaro and Ozempic — and where it sits relative to bariatric surgery, which for many patients with significant obesity remains the most effective and durable treatment available.
If you are considering starting Foundayo in Dubai under proper medical supervision, or want to understand whether surgery or medication is right for your situation, book a consultation below.
What Is Foundayo? (Orforglipron Explained)
Foundayo is the brand name for orforglipron, a non-peptide, small-molecule GLP-1 receptor agonist. It was developed by Eli Lilly — the same company behind Mounjaro (tirzepatide) — and represents a genuine pharmacological breakthrough: the first GLP-1 weight loss medicine that works as an oral tablet.
Existing GLP-1 medications (Ozempic, Mounjaro, Wegovy, Saxenda) are all peptide-based. Because peptides are broken down by stomach acid and digestive enzymes, they must be administered by subcutaneous injection. Orforglipron is chemically different — a small organic molecule that survives digestion and can be absorbed through the gut wall after swallowing.
It was approved by the US FDA on 1 April 2026 and by the UAE’s Emirates Drug Establishment (EDE) in April 2026. The UAE became the second country in the world to authorise it. It is expected to be available in UAE pharmacies from May 2026.
Key Advantages of Foundayo Over Injectable GLP-1 Drugs
- No injections — a daily tablet, ideal for patients who are needle-averse
- No food or water restrictions — unlike oral semaglutide, which requires fasting for 30 minutes before and after
- No refrigeration — stable at room temperature; important for UAE climate and travel
- Lower cost — estimated AED 550–800/month vs AED 1,734–2,000/month for Mounjaro
- Once-daily dosing — starting at 1 mg, titrated up to 6 mg, 12 mg, or 36 mg
How Does Foundayo Work for Weight Loss?
Foundayo activates GLP-1 receptors in the brain, gut, and pancreas. GLP-1 (glucagon-like peptide-1) is a hormone your body naturally releases after eating. When GLP-1 receptors are stimulated continuously by orforglipron, several things happen:
Appetite suppression — you feel full sooner and remain satisfied for longer between meals
Delayed gastric emptying — the stomach empties more slowly, reducing post-meal blood sugar spikes and prolonging satiety
Improved insulin secretion — glucose-dependent insulin release is enhanced, benefiting patients with or at risk of Type 2 diabetes
Reduced food cravings — GLP-1 receptor activation in the brain modulates the reward response to food
Because Foundayo maintains continuous receptor stimulation throughout the day, patients consistently consume fewer calories over time, producing the sustained caloric deficit required for meaningful weight reduction.
Foundayo Clinical Trial Results: How Much Weight Will You Lose?
The ATTAIN-1 Phase 3 trial (New England Journal of Medicine, September 2025) enrolled 3,127 non-diabetic adults with obesity or overweight plus at least one weight-related comorbidity. Participants were randomised to placebo or one of three daily doses of orforglipron for 72 weeks.
| Dose | Average Body Weight Lost | vs Placebo (2.1%) |
|---|---|---|
| 6 mg / day | 7.8% of body weight | +5.7 pp |
| 12 mg / day | 9.3% of body weight | +7.2 pp |
| 36 mg / day | 12.4% of body weight | +10.3 pp |
| Average across all doses | ~12.3 kg per person | Statistically significant (p<0.001) |
Source: ATTAIN-1 trial, NEJM 2025. Results over 72 weeks alongside diet and physical activity guidance.
The ATTAIN-2 trial (2026) confirmed similar weight loss outcomes in adults with obesity and Type 2 diabetes, alongside improvements in HbA1c, non-HDL cholesterol, systolic blood pressure, and triglycerides.
A separate ATTAIN-MAINTAIN study showed that patients who had already lost significant weight on injectable GLP-1s (Wegovy or Zepbound) and then switched to Foundayo were able to maintain those results — making it a practical long-term option for patients transitioning off injections.
Who Is Foundayo Prescribed For in the UAE?
Following EDE approval, Foundayo is indicated for adults meeting the following criteria:
BMI ≥ 30 kg/m² (clinically obese)
BMI ≥ 27 kg/m² with at least one weight-related comorbidity: Type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease
Foundayo is NOT suitable if you:
Have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Are already taking another GLP-1 receptor agonist (Ozempic, Mounjaro, Wegovy, Saxenda — cannot be combined)
Have had a serious allergic reaction to orforglipron
Are pregnant or trying to conceive
A clinical assessment by a qualified physician is mandatory before starting Foundayo. This is not a medication you should obtain without a full medical evaluation. |
Foundayo Side Effects: What to Expect
The safety profile of Foundayo is consistent with the wider GLP-1 drug class. The most commonly reported adverse effects are gastrointestinal and are generally mild to moderate, particularly during dose escalation.
Common Side Effects
Nausea
Vomiting
Diarrhoea
Constipation
Dyspepsia (indigestion or heartburn)
Less Common Side Effects
Fatigue, particularly in early weeks
Reduced appetite (partly the intended mechanism)
Abdominal discomfort or bloating
Serious Warnings (Rare)
Foundayo carries a black box warning — consistent with all GLP-1 drugs — for potential thyroid C-cell tumours, including thyroid cancer, seen in animal studies. Patients should watch for: a lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath.
In the ATTAIN-1 trial, treatment discontinuation rates due to adverse events ranged from 6.1% at 6 mg to 10.6% at 36 mg — comparable to other approved GLP-1 therapies. Dr. Rahmani’s supervised programmes begin at the lowest dose (1 mg) with a gradual step-up to manage tolerability.
Foundayo vs Mounjaro vs Ozempic: Side-by-Side Comparison
Here is how Foundayo compares to the other principal GLP-1 weight loss medications available in the UAE:
| Feature | Foundayo™ (Orforglipron) | Mounjaro™ (Tirzepatide) | Ozempic® (Semaglutide) |
|---|---|---|---|
| Manufacturer | Eli Lilly | Eli Lilly | Novo Nordisk |
| Drug Class | Small molecule GLP-1 agonist | GIP + GLP-1 dual agonist (peptide) | GLP-1 agonist (peptide) |
| Form | Daily oral tablet | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Avg. Weight Loss | ~12% body weight (72 wks) | ~20–22% body weight (72 wks) | ~15–17% body weight (68 wks)600–900 |
| Food Restrictions | None — take any time | None | None |
| Refrigeration | Not required | Required before first use | Required before first use |
| UAE Status | Approved April 2026 (EDE) | Approved — widely available | Approved — widely available |
| Est. UAE Monthly Cost | ~AED 550–800 (est.) | ~AED 1,734–2,000 | ~AED 744–1,200 |
| Best Candidate | Needle-averse; cost-conscious; maintenance after injectables | Patients needing maximum pharmacological weight loss | Established option; T2D with weight loss goal |
| Suitable for T2D | Yes (ATTAIN-2 confirmed) | Yes (primary label) | Yes (primary indication) |
UAE pricing as of May 2026: Foundayo UAE pricing to be confirmed by EDE/Eli Lilly. Consult clinic for current figures.
Foundayo vs Bariatric Surgery: Which Delivers Better Results?
This is the most important comparison for patients with significant obesity. While Foundayo represents real progress in weight loss pharmacology, it is important to be clinically honest: for patients who qualify, bariatric surgery consistently delivers greater, faster, and more durable weight loss than any medication currently available — including Foundayo.
Here is a full clinical comparison:
| Factor | Foundayo™ (Orforglipron) | Bariatric Surgery (Sleeve / Bypass) |
|---|---|---|
| Average Weight Loss |  ~12% of body weight |  25–30%+ of body weight |
| Speed of Results | Gradual — 12–18 months to peak | Significant loss within 3–6 months |
| Durability | Weight often returns if medication stopped | Long-term loss maintained in majority of patients (10+ years data) |
| Diabetes Remission | Improves glycaemic control; does not typically induce remission | Type 2 diabetes goes into full remission in 60–80% of gastric bypass patients |
| Cardiovascular Benefit | Moderate improvement in BP, lipids, CRP | Major reduction in cardiovascular mortality demonstrated in long-term studies |
| Metabolic Comorbidity Resolution | Partial improvement | Hypertension, sleep apnoea, NAFLD, dyslipidaemia — high resolution rates |
| Invasiveness | Non-invasive oral tablet | Surgical procedure under general anaesthetic |
| Recovery Time | None | 2–6 weeks; dietary progression over 3–6 months |
| Reversibility | Stop tablet at any time | Largely irreversible (especially bypass) |
| BMI Eligibility | BMI ≥30 (or ≥27 with comorbidities) | Typically BMI ≥40 (or ≥35 with comorbidities); broader access in UAE |
| Ongoing Maintenance | Continued medication costs indefinitely | One-time procedure; lower long-term pharmacological cost |
| UAE One-Time Cost | AED 550–800/month ongoing (AED 6,600–9,600+/yr) | AED 40,000–120,000 one-time; cost-effective |
| long-term for appropriate patients | ||
| Side Effect Profile | Mild–moderate GI effects in some patients | Surgical risks (small but real), nutritional deficiency risk, dumping syndrome |
= Stronger outcome on this factor = Weaker or more complex outcome. Data from ATTAIN-1 (2025), NEJM Bariatric Surgery landmark trials, IFSO 2024 guidelines.
| Clinical Verdict: For patients with BMI ≥35 or BMI ≥30 with significant comorbidities, bariatric surgery remains the gold standard for weight loss — delivering roughly twice the weight reduction of Foundayo, with proven long-term durability, diabetes remission rates that no medication can match, and decades of global safety data. Foundayo is a meaningful advance in pharmacotherapy. It is not a surgical replacement. |
So When Is Foundayo the Right Choice?
Foundayo is not a lesser option — it is simply the right tool for a different patient profile. Here is how Dr. Rahmani approaches this decision in clinic:
| Patient Situation | Recommended Pathway |
|---|---|
| BMI ≥40, or ≥35 with T2D / hypertension / sleep apnea | Bariatric surgery should be the primary discussion. Medication may be used as a bridge to reduce pre-operative risk. |
| BMI 30–35, not yet eligible or not ready for surgery | Foundayo or Mounjaro as first-line pharmacotherapy, with surgery discussed if plateau is reached. |
| Needle-averse patient needing GLP-1 therapy | Foundayo is the preferred pharmacological option. |
| Post-surgery patient wanting to maintain results | Foundayo can assist weight maintenance if regain occurs after surgery. |
| Patient who lost weight on Mounjaro/Wegovy wanting to transition off injections | Foundayo as maintenance therapy — supported by the ATTAIN-MAINTAIN trial data. |
| Patient with T2D and moderate obesity (BMI 27–35) | Foundayo or Mounjaro depending on the degree of glycaemic control required; surgery for severe cases. |
| Patient who has failed multiple pharmacotherapy courses | Bariatric surgery should be strongly considered as the definitive treatment. |
| Dr. Rahmani’s approach: medication and surgery are not competing — they are complementary tools. The right choice depends on your BMI, comorbidities, goals, and readiness. We discuss all options in full at your consultation. |
Foundayo Price in UAE & Dubai: What Does It Cost?
As of May 2026, Foundayo has been approved in the UAE but official retail pharmacy pricing has not yet been confirmed by Eli Lilly UAE or the EDE. Based on current US pricing data:
US self-pay price: USD $149/month at lowest dose (≈ AED 547)
Estimated UAE retail: AED 550–800/month (based on existing GLP-1 pricing ratios)
Compare to Mounjaro: ~AED 1,734–2,000/month
Compare to Ozempic: ~AED 744–1,200/month
UAE insurance coverage: GLP-1 drugs for weight loss are not currently covered by standard UAE health insurance (only for confirmed Type 2 diabetes)
Foundayo is likely to be the most affordable GLP-1 option in the UAE once pricing is confirmed. For patients who cannot afford Mounjaro but want a medically proven GLP-1 treatment, this is a significant development.
For current pricing and availability at Dr. Rahmani’s clinic, contact us directly.
How to Get Foundayo in Dubai — Legally and Safely
Foundayo is a prescription-only medication in the UAE. Do not purchase it from unverified online sources. The UAE has documented cases of counterfeit and grey-market GLP-1 medications posing serious patient safety risks.
The correct process through Dr. Rahmani’s clinic:
Book a weight management consultation for clinical assessment (BMI, blood panel, health history, current medications)
Receive a formal diagnosis and treatment plan tailored to your goals
If suitable, receive a UAE prescription for Foundayo with a structured dose-escalation schedule
Collect from a licensed UAE pharmacy (availability from May 2026)
Regular follow-up to monitor results, manage side effects, and adjust dosing as needed
Foundayo vs Mounjaro vs Ozempic: Side-by-Side Comparison
Here is how Foundayo compares to the other principal GLP-1 weight loss medications available in the UAE:
| Feature | Foundayo™ (Orforglipron) | Mounjaro™ (Tirzepatide) | Ozempic® (Semaglutide) |
|---|---|---|---|
| Manufacturer | Eli Lilly | Eli Lilly | Novo Nordisk |
| Drug Class | Small molecule GLP-1 agonist | GIP + GLP-1 dual agonist (peptide) | GLP-1 agonist (peptide) |
| Form | Daily oral tablet | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Avg. Weight Loss | ~12% body weight (72 wks) | ~20–22% body weight (72 wks) | ~15–17% body weight (68 wks)600–900 |
| Food Restrictions | None — take any time | None | None |
| Refrigeration | Not required | Required before first use | Required before first use |
| UAE Status | Approved April 2026 (EDE) | Approved — widely available | Approved — widely available |
| Est. UAE Monthly Cost | ~AED 550–800 (est.) | ~AED 1,734–2,000 | ~AED 744–1,200 |
| Best Candidate | Needle-averse; cost-conscious; maintenance after injectables | Patients needing maximum pharmacological weight loss | Established option; T2D with weight loss goal |
| Suitable for T2D | Yes (ATTAIN-2 confirmed) | Yes (primary label) | Yes (primary indication) |
UAE pricing as of May 2026. Foundayo UAE pricing to be confirmed by EDE/Eli Lilly. Consult clinic for current figures.
Foundayo vs Bariatric Surgery: Which Delivers Better Results?
This is the most important comparison for patients with significant obesity. While Foundayo represents real progress in weight loss pharmacology, it is important to be clinically honest: for patients who qualify, bariatric surgery consistently delivers greater, faster, and more durable weight loss than any medication currently available — including Foundayo.
Here is a full clinical comparison:
| Factor | Foundayo™ (Orforglipron) | Bariatric Surgery (Sleeve / Bypass) |
|---|---|---|
| Average Weight Loss | ⚠ ~12% of body weight | ✅ 25–30%+ of body weight |
| Speed of Results | ⚠ Gradual — 12–18 months to peak | ✅ Significant loss within 3–6 months |
| Durability | ⚠ Weight often returns if medication stopped | ✅ Long-term loss maintained in majority of patients (10+ years data) |
| Diabetes Remission | ⚠ Improves glycaemic control; does not typically induce remission | ✅ Type 2 diabetes goes into full remission in 60–80% of gastric bypass patients |
| Cardiovascular Benefit | ⚠ Moderate improvement in BP, lipids, CRP | ✅ Major reduction in cardiovascular mortality demonstrated in long-term studies |
| Metabolic Comorbidity Resolution | ⚠ Partial improvement | ✅ Hypertension, sleep apnoea, NAFLD, dyslipidaemia — high resolution rates |
| Invasiveness | ✅ Non-invasive oral tablet | ⚠ Surgical procedure under general anaesthetic |
| Recovery Time | ✅ None | ⚠ 2–6 weeks; dietary progression over 3–6 months |
| Reversibility | ✅ Stop tablet at any time | ⚠ Largely irreversible (especially bypass) |
| BMI Eligibility | ⚠ BMI ≥30 (or ≥27 with comorbidities) | ✅ Typically BMI ≥40 (or ≥35 with comorbidities); broader access in UAE |
| Ongoing Maintenance | ⚠ Continued medication costs indefinitely | ✅ One-time procedure; lower long-term pharmacological cost |
| UAE One-Time Cost | ⚠ AED 550–800/month ongoing (AED 6,600–9,600+/yr) | ✅ AED 40,000–120,000 one-time; cost-effective |
| long-term for appropriate patients | ||
| Side Effect Profile | ✅ Mild–moderate GI effects in some patients | ⚠ Surgical risks (small but real), nutritional deficiency risk, dumping syndrome |
✅ = Stronger outcome on this factor ⚠ = Weaker or more complex outcome. Data from ATTAIN-1 (2025), NEJM Bariatric Surgery landmark trials, IFSO 2024 guidelines.
| Clinical Verdict: For patients with BMI ≥35 or BMI ≥30 with significant comorbidities, bariatric surgery remains the gold standard for weight loss — delivering roughly twice the weight reduction of Foundayo, with proven long-term durability, diabetes remission rates that no medication can match, and decades of global safety data. Foundayo is a meaningful advance in pharmacotherapy. It is not a surgical replacement. |
So When Is Foundayo the Right Choice?
Foundayo is not a lesser option — it is simply the right tool for a different patient profile. Here is how Dr. Rahmani approaches this decision in clinic:
| Patient Situation | Recommended Pathway |
|---|---|
| BMI ≥40, or ≥35 with T2D / hypertension / sleep apnea | Bariatric surgery should be the primary discussion. Medication may be used as a bridge to reduce pre-operative risk. |
| BMI 30–35, not yet eligible or not ready for surgery | Foundayo or Mounjaro as first-line pharmacotherapy, with surgery discussed if plateau is reached. |
| Needle-averse patient needing GLP-1 therapy | Foundayo is the preferred pharmacological option. |
| Post-surgery patient wanting to maintain results | Foundayo can assist weight maintenance if regain occurs after surgery. |
| Patient who lost weight on Mounjaro/Wegovy wanting to transition off injections | Foundayo as maintenance therapy — supported by the ATTAIN-MAINTAIN trial data. |
| Patient with T2D and moderate obesity (BMI 27–35) | Foundayo or Mounjaro depending on the degree of glycaemic control required; surgery for severe cases. |
| Patient who has failed multiple pharmacotherapy courses | Bariatric surgery should be strongly considered as the definitive treatment. |
| Dr. Rahmani’s approach: medication and surgery are not competing — they are complementary tools. The right choice depends on your BMI, comorbidities, goals, and readiness. We discuss all options in full at your consultation. |
Foundayo Price in UAE & Dubai: What Does It Cost?
As of May 2026, Foundayo has been approved in the UAE but official retail pharmacy pricing has not yet been confirmed by Eli Lilly UAE or the EDE. Based on current US pricing data:
- US self-pay price: USD $149/month at lowest dose (≈ AED 547)
- Estimated UAE retail: AED 550–800/month (based on existing GLP-1 pricing ratios)
- Compare to Mounjaro: ~AED 1,734–2,000/month
- Compare to Ozempic: ~AED 744–1,200/month
- UAE insurance coverage: GLP-1 drugs for weight loss are not currently covered by standard UAE health insurance (only for confirmed Type 2 diabetes)
Foundayo is likely to be the most affordable GLP-1 option in the UAE once pricing is confirmed. For patients who cannot afford Mounjaro but want a medically proven GLP-1 treatment, this is a significant development.
For current pricing and availability at Dr. Rahmani’s clinic, contact us directly.
How to Get Foundayo in Dubai — Legally and Safely
Foundayo is a prescription-only medication in the UAE. Do not purchase it from unverified online sources. The UAE has documented cases of counterfeit and grey-market GLP-1 medications posing serious patient safety risks.
The correct process through Dr. Rahmani’s clinic:
- Book a weight management consultation for clinical assessment (BMI, blood panel, health history, current medications)
- Receive a formal diagnosis and treatment plan tailored to your goals
- If suitable, receive a UAE prescription for Foundayo with a structured dose-escalation schedule
- Collect from a licensed UAE pharmacy (availability from May 2026)
- Regular follow-up to monitor results, manage side effects, and adjust dosing as needed
Why Choose Dr. Samir Rahmani for Weight Loss Treatment in Dubai?
Dr. Samir Rahmani is a specialist in bariatric and weight management medicine based in Dubai, with extensive clinical experience in both surgical and non-surgical weight loss interventions.
Specialist expertise in bariatric surgery including gastric sleeve and gastric bypass
Extensive experience prescribing GLP-1 therapies: Mounjaro, Ozempic, Saxenda, and oral semaglutide
Early adopter of Foundayo — offering it from May 2026 launch as part of supervised programmes
Evidence-based approach: recommendations based on your clinical data, not generic protocols
Registered with DHA (Dubai Health Authority)
Arabic and English-speaking clinic team
Whether Foundayo, Mounjaro, or bariatric surgery is the right answer for you depends on your individual health picture. Many patients benefit from a clear, honest conversation about all the options before committing to any treatment pathway.
Explore Other Weight Loss Treatments Available in Dubai
Dr. Rahmani offers a full range of medically supervised weight loss treatments. Compare your options:
Mounjaro (Tirzepatide) Dubai — the highest-efficacy injectable GLP-1 available in the UAE
Ozempic (Semaglutide) Dubai — established weekly injection with strong long-term safety data
Weight Loss Injections & Pills — complete guide to all approved GLP-1 options in the UAE
Bariatric Surgery Dubai — gastric sleeve, gastric bypass, and mini gastric bypass for significant obesity.
Start Your Weight Loss Journey in Dubai — Pill, Injection, or Surgery
Foundayo is a genuine advance in obesity pharmacotherapy — a medically proven oral option that is finally accessible in the UAE. For the right patient, it is an excellent treatment.
But meaningful, lasting weight loss — particularly for patients with significant obesity or multiple comorbidities — often requires more than a pill. Dr. Rahmani’s clinic offers the full spectrum of evidence-based weight loss treatment: from Foundayo and Mounjaro to bariatric surgery and combined programmes. We help you find the right pathway for your body, your health, and your goals.
Book a Consultation with Dr. Samir Rahmani
Frequently Asked Questions About Foundayo (Orforglipron) in UAE
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist tablet developed by Eli Lilly for weight management. It is the first GLP-1 weight loss pill that can be taken at any time of day without food or water restrictions. The UAE became the second country in the world to approve it in April 2026, following the US FDA approval on 1 April 2026.
Yes. Foundayo was approved by the UAE Emirates Drug Establishment (EDE) in April 2026 and is available in UAE pharmacies from May 2026. It is a prescription-only medication and must be obtained through a licensed UAE physician.
Official UAE pharmacy pricing has not yet been confirmed by Eli Lilly. Based on the US self-pay price ($149/month, approximately AED 547), the estimated UAE cost is AED 550–800 per month. This makes it likely the most affordable GLP-1 treatment option in the UAE. Contact Dr. Rahmani’s clinic for current confirmed pricing.
Both are made by Eli Lilly. Mounjaro is a weekly injection that targets both GLP-1 and GIP receptors, producing ~20–22% body weight loss on average. Foundayo is a daily oral tablet targeting only GLP-1, producing ~12% body weight loss. Mounjaro delivers significantly greater weight loss but requires injections and costs more (~AED 1,734–2,000/month vs estimated AED 550–800/month for Foundayo). For patients who are needle-averse or cost-conscious, Foundayo is a more practical alternative.
No — for patients who are eligible, bariatric surgery produces substantially greater and more durable weight loss than Foundayo or any other GLP-1 medication. Surgery delivers an average 25–30% body weight reduction compared to Foundayo’s ~12%, with long-term durability, high rates of Type 2 diabetes remission, and well-established cardiovascular benefits. Foundayo is the right choice for patients who are not eligible for surgery, not ready for it, or who prefer to try pharmacotherapy first. A consultation with Dr. Rahmani will clarify which pathway suits your specific situation.
The most common Foundayo side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and indigestion. These are generally mild to moderate and most common during dose escalation. Foundayo carries a black box warning for potential thyroid tumours (consistent with all GLP-1 drugs). A full medical consultation is required before starting to assess your individual risk.
No. Foundayo must not be taken alongside any other GLP-1 receptor agonist including Mounjaro, Ozempic, Wegovy, or Saxenda. Always disclose all current medications to your prescribing physician.
Patients with a BMI of 40 or above, or BMI 35+ with serious comorbidities such as Type 2 diabetes, severe hypertension, or obstructive sleep apnoea, should discuss bariatric surgery with Dr. Rahmani. Surgery delivers roughly twice the weight loss of Foundayo, with documented long-term durability and high rates of diabetes remission that no weight loss pill can currently replicate. Foundayo may be used as a pre-operative tool to reduce BMI and surgical risk.
Medical Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified health provider with any questions you may have regarding a medical condition.
Medically reviewed by Dr. Samir Rahmani.